Carisma Therapeutics, Inc.
OTC: CARM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Craig R. Jalbert
- Employees
- 46
- Headquarters
- Philadelphia, United States
- IPO year
- 2014
- Market cap
- $338.9K
- Website
- https://www.carismatx.com
Loading CARM…
Loading profile data…Frequently asked questions about CARM
What does Carisma Therapeutics, Inc. (CARM) do?
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in ph...
Where does CARM trade?
Carisma Therapeutics, Inc. (CARM) trades on the Other OTC.
What sector is CARM in?
Carisma Therapeutics, Inc. (CARM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Carisma Therapeutics, Inc.?
Craig R. Jalbert is the chief executive officer of Carisma Therapeutics, Inc. (CARM).
Where is Carisma Therapeutics, Inc. headquartered?
Carisma Therapeutics, Inc. is headquartered in United States.
Does CARM pay a dividend?
Carisma Therapeutics, Inc. (CARM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CARM go public?
Carisma Therapeutics, Inc. (CARM) completed its initial public offering in 2014.